Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma
Titel:
Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma
Auteur:
Moreno, V. Sepulveda, J.M. Vieito, M. Hernández-Guerrero, T. Doger, B. Saavedra, O. Ferrero, O. Sarmiento, R. Arias, M. De Alvaro, J. Di Martino, J. Zuraek, M. Sanchez-Pérez, T. Aronchik, I. Filvaroff, E.H. Lamba, M. Hanna, B. Nikolova, Z. Braña, I.